- Opinion: How a controversial rule could hurt the NIH’s ability to manage riskThe proposed rule could “weaken the NIH’s benign influence over research risks,” writes Doni Bloomfield.STAT · 6d ago↗ source
- Opinion: Science and the public are learning the wrong lessons from Covid“Post-pandemic polarization threatens to lock our memories into attractive, untrue conclusions that will leave us unprotected next time,” write Marc Lipsitch and Sara Cody.STAT · 6d ago↗ source
- STAT+: Makers of rare disease drugs seek exemption from Trump’s price-cut pilotsA coalition of biotech firms is lobbying to exclude orphan drugs from new federal pilot programs aimed at lowering Medicare drug costs.STAT · 6d ago